Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENC · IEX Real-Time Price · USD
8.67
+0.14 (1.64%)
Nov 29, 2023, 10:54 AM EST - Market open
1.64%
Market Cap 232.11M
Revenue (ttm) 13.05M
Net Income (ttm) -20.22M
Shares Out 26.71M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE 154.87
Dividend n/a
Ex-Dividend Date n/a
Volume 2,031
Open 8.50
Previous Close 8.53
Day's Range 8.50 - 8.69
52-Week Range 6.30 - 10.85
Beta 0.24
Analysts Strong Buy
Price Target 15.00 (+73.01%)
Earnings Date Nov 6, 2023

About FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in R... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 5, 2001
Employees 36
Stock Exchange NASDAQ
Ticker Symbol FENC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 73.01% from the latest price.

Price Target
$15.0
(73.01% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

19 days ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 202...

23 days ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

4 weeks ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

~ Growing Physician Awareness and Usage of PEDMARK ® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Managem...

4 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

4 months ago - GlobeNewsWire

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...

6 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Pedmarqsi™ is the First and Only Approved Therapy in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid...

6 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

~ Strong PEDMARK ® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~

8 months ago - GlobeNewsWire

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ® in September 2022 ~

8 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

10 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,  Non-metastatic Solid Tumors ~

11 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ In September 2022, FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Me...

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of...

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

~ PEDMARK TM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

1 year ago - GlobeNewsWire

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ ~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~

1 year ago - GlobeNewsWire

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "...

1 year ago - Business Wire

FENC FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

New York, New York--(Newsfile Corp. - April 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) betwe...

1 year ago - Newsfile Corp

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fennec Investors of a Lead Plaintiff Deadline of April 11, 2022

NEW YORK , April 11, 2022 /PRNewswire/ -- Attention Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenc...

1 year ago - PRNewsWire